



Treatment of Hepatitis C

Prior Authorization Guidelines

Effective: January 1, 2022

Introduction:

Hepatitis C has been identified as a significant etiology of chronic liver disease, associated comorbidities, liver cancer, need for transplantation and death. These guidelines document eligible beneficiaries and the information that must be submitted in order to determine a coverage determination. Modifications to the Preferred Drug List require approval by the Rhode Island Medicaid Pharmacy and Therapeutics Committee.

Detailed prescribing and drug warning information may be obtained at:

<http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm>

Prior Authorization is required for medications not on the Preferred Drug List.

General Approval Criteria:

- A. Prescribers must be enrolled as a billing provider or an ordering, prescribing or referring (OPR) provider with Rhode Island Medicaid.
- B. Beneficiaries:
 - i. All patients with documented Hepatitis C Stages 0 through 4 are eligible for treatment.
- C. Required Documentation:
 - i. Prior Authorization is not required when prescribing Mavyret®.
 - ii. Prior Authorization is not required for prescribing Vosevi® when used as a salvage medication after prior treatment failure. See package insert for FDA approved indication, and prescribing information.
 - iii. Neither Mavyret® nor Vosevi® require genotyping.
 - iv. Treatment request for non-preferred, non-panogenic medications require genotyping.
 - v. History of prior Hepatitis C treatment if request is for non-preferred medication
 - vi. Treatment plan which includes:
 - i. Medication name, dose and duration.
 - ii. Agreement to submit post treatment viral load data if requested.
- D. Treatment recommendations as of January 1, 2022:
 - i. Preferred agents: Mavyret® and Vosevi®.
 - ii. Non preferred agents:
 - i. Will be approved if patient is completing a cycle of therapy initiated prior to current policy implementation date, or

- ii. Will be reviewed on a case-by-case basis. The Prior Authorization request must include clinical documentation of need for an alternative, non-preferred agent.
- E. Continuity of Treatment:
 - i. When transitioning between publicly funded delivery systems (i.e., between Fee for Service Medicaid and managed Care Medicaid, between managed Care Medicaid and Fee for Service Medicaid or between the Department of Corrections and the Medicaid Program) any medication approval by the prior delivery system will be honored for the portion of the treatment that remains after the transition.
- F. Policy Effective Date: January 1, 2022.
 - i. Above policy replaces all prior Hepatitis C policies including revision with implementation date of August 1, 2021.

Approved:

Jerry Fingerut, MD.

Date:

December 13, 2021